For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise

A new study suggests that patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from treatments known as immune checkpoint inhibitors. An NCI-sponsored clinical trial is already testing one such drug in patients with this cancer.

http://ift.tt/2o4MZs3